CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 29 enrolled
Drug / intervention
Carvedilol +1 moredrug
Likely dose
Carvedilol 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01354444
NCT01354444Phase 4Completed
CompareCT.gov

Pilot Trial of Carvedilol in Alzheimer's Disease

Johns Hopkins University·interventional·Posted May 16, 2011·Updated Feb 6, 2018

In Brief

A Phase 4 clinical trial evaluating Carvedilol and Placebo for Alzheimer's Disease. Completed, enrolled 29 participants across 1 site.

Detailed Summary

This is a 6-month pilot randomized double-blind placebo-controlled trial of carvedilol, with the primary objective being to determine whether carvedilol treatment is associated with improvement in Alzheimer's Disease (AD) as compared to placebo treatment. Secondary objectives are to monitor changes in cerebrospinal fluid amyloid levels and whether this dose will be safe and well-tolerated in AD patients. Clinical assessments will be performed at baseline, 3 months, and 6 months, while cerebrospinal fluid and blood samples will be obtained at baseline and 6 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsIcahn School of Medicine at Mount Sinai

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 16, 2011
Enrollment StartJun 1, 2011
Primary CompletionDec 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 15.1 years ago

Interventions

Carvediloldrug

target dose of 25 mg daily which is half the maximum dose used in clinical practice

Placebodrug

a pill that will look like the active drug but will not contain any carvedilol